Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 5, n. 6, p. s52, 2021. DOI: 10.25251/skin.5.supp.52. Disponível em: https://skin.dermsquared.com/skin/article/view/1403. Acesso em: 30 apr. 2026.